Drug Type Antibody fusion proteins |
Synonyms Anti-IL-17 antibody-TACI fusion protein(Simcere Pharmaceutical) |
Target |
Mechanism IL-17 inhibitors(Interleukin-17 inhibitors), TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | CN | 11 Jul 2024 |